Printer Friendly
The Free Library
5,060,680 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Astellas Discontinues Development of Immunosuppressant FK778.


Tokyo, Japan, June 30, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
 Newswire) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社   Inc. today announced that it has decided to discontinue development of FK778, an immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses.

im·mu·no·sup·pres·sant
n.
An agent that suppresses the body's immune response.
.

Astellas started Phase-II trials for FK778 for organ transplants organ transplant: see transplantation, medical.  in combination with Prograf(R) in the US and Europe. After careful review of the Phase-II clinical data on FK778, however, Astellas has decided to discontinue further development of FK778 in organ transplantation The transfer of organs such as the kidneys, heart, or liver from one body to another.

The transplantation of human organs has become a common medical procedure. Typical organs transplanted are the kidneys, heart, liver, pancreas, cornea, skin, bones, and lungs.
 since the data reviewed did not indicate clear benefits over current treatment options in combination with Prograf(R).

Astellas is committed to immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic  and the transplant community and will continue its leading-edge research and development program, exploring new treatment options that provide meaningful advancement over current therapies, for years to come.

About Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit the company's website at www.astellas.com.

Source: Astellas Pharma Inc.

Contact:
Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201 Fax: +81-3-5201-7473
http://www.astellas.com


Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:9JAPA
Date:Jun 30, 2006
Words:249
Previous Article:NEC Enables Single Sign-on for Mobile Services at Telefonica Moviles Espana.
Next Article:Sanix Issues Notice Regarding Conversion of First Series of Unsecured Convertible Bonds with Stock Acquisition Rights.
Topics:



Related Articles
Astellas Pharma, Theravance to Enter into Licensing Agreement for Investigational Antibiotic Telavancin.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Astellas Establishes New Subsidiary 'Astellas Pharma Chemicals Co., Ltd.'.
Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of Hyperphosphatemia in Japan.
Astellas Discontinues Development of Alzheimer's Disease Compound FK962.
ASTELLAS' SCREENING TRIGGERS MILESTONE PAYMENT TO METABOLEX.
ASPERVA REPORTS ON PHASE III TRIAL FOR MYASTHENIA GRAVIS.
Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.
Kirin and Astellas Enter Into Licensing Agreement on Immunosuppressive Fully Human Monoclonal Antibody.
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles